SCHEMBL609868

SCHEMBL609868

Cn1c(=O)c2c(cnn2CC(=O)Nc2nc(-c3cc(Cl)c(OCC(C)(C)C)c(Cl)c3)cs2)n(C)c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 16/20 1.00
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL612181 0.95 TRPA1 (0.90) TRPA1MAPT
SCHEMBL15746154 0.91 TRPA1 (0.84) TRPA1MAPTSMN1; SMN2LMNA
SCHEMBL609734 0.91 TRPA1 (0.83) TRPA1MAPTSMN1; SMN2
SCHEMBL480936 0.91 TRPA1 (0.83) TRPA1MAPT
SCHEMBL609586 0.89 TRPA1 (0.80) TRPA1MAPTSMN1; SMN2LMNA
SCHEMBL10171371 0.88 TRPA1 (0.79) TRPA1MAPTSMN1; SMN2LMNA
SCHEMBL611758 0.87 TRPA1 (0.77) TRPA1MAPTSMN1; SMN2LMNA
SCHEMBL10139363 0.87 TRPA1 (0.77) TRPA1MAPTSMN1; SMN2LMNA
SCHEMBL612533 0.87 TRPA1 (0.80) TRPA1MAPTSMN1; SMN2LMNA
SCHEMBL2445031 0.86 TRPA1 (0.76) TRPA1MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411393-B1 FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2014-01-22 EP claimed
US-20120041004-A1 FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-02-16 US claimed
US-20160158236-A1 PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID GLENMARK PHARMACEUTICALS S.A. (CH) 2016-06-09 US disclosed
US-20160158236-A1 PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID GLENMARK PHARMACEUTICALS S.A. (CH) 2016-06-09 US disclosed
US-9186360-B2 Treatment of respiratory disorders using TRPA1 antagonists GLENMARK PHARMACEUTICALS S.A. (CH) 2015-11-17 US disclosed
US-9186360-B2 Treatment of respiratory disorders using TRPA1 antagonists GLENMARK PHARMACEUTICALS S.A. (CH) 2015-11-17 US disclosed
EP-2708538-B1 Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators GLENMARK PHARMACEUTICALS SA (CH) 2015-08-12 EP disclosed
US-9000159-B2 Fused pyrimidine-dione derivatives as TRPA1 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2015-04-07 US disclosed
US-9000159-B2 Fused pyrimidine-dione derivatives as TRPA1 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2015-04-07 US disclosed
US-9000159-B2 Fused pyrimidine-dione derivatives as TRPA1 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2015-04-07 US disclosed
US-20140364445-A1 PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND AN ANTICHOLINERGIC AGENT GLENMARK PHARMACEUTICALS S.A. (CH) 2014-12-11 US disclosed
US-20140128603-A1 FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2014-05-08 US disclosed
EP-2708538-A1 Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators Glenmark Pharmaceuticals S.A. (CH) 2014-03-19 EP disclosed
EP-2411393-B1 FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2014-01-22 EP disclosed
US-8623880-B2 Fused pyrimidine-dione derivatives as TRPA1 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2014-01-07 US disclosed
US-8623880-B2 Fused pyrimidine-dione derivatives as TRPA1 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2014-01-07 US disclosed
US-8623880-B2 Fused pyrimidine-dione derivatives as TRPA1 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2014-01-07 US disclosed
US-20120316136-A1 TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-12-13 US disclosed
US-20120041004-A1 FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-02-16 US disclosed
US-20120041004-A1 FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364445-A1 PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND AN ANTICHOLINERGIC AGENT TRPA1, TRPV1, TRPV5 TRPA1 1/4885MAPT 404/4885SMN1; SMN2 930/4885
US-20140128603-A1 FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS TRPA1, TRPV1, TRPV2 TRPA1 1/4885MAPT 1998/4885SMN1; SMN2 2770/4885
US-20120316136-A1 TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS TRPA1, TRPV1, TRPV2 TRPA1 1/4885MAPT 2700/4885SMN1; SMN2 1149/4885
US-20160158236-A1 PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID TRPA1, TRPV1, TRPV2 TRPA1 1/4885MAPT 503/4885SMN1; SMN2 1572/4885
US-20120041004-A1 FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS TRPA1, TRPV1, TRPC3 TRPA1 1/4885MAPT 2007/4885SMN1; SMN2 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.